Financings

Dendreon Corp. raised $125 million by monetizing its share of royalties on Victrelis (boceprevir).

EMBL Ventures GmbH closed a $53.5 million fund for German life science companies.

Forbion Capital Partners closed its second FCF 1 Co-Investment Fund at about $50 million.

Gilead Sciences Inc. priced $3.7 billion worth of senior unsecured notes in a public offering.

Deals

Biogen Idec Inc. entered a $300 million joint venture with Samsung for biosimilars.

Medicis Pharmaceutical Corp. acquired the assets of Graceway Pharmaceuticals LLC for $455 million.

Molecular Partners AG signed an immunology discovery deal with Janssen Biotech Inc.

Momenta Pharmaceuticals Inc. acquired Virdante Pharmaceuticals Inc.'s protein sialylation programs.

. . . And More

See BioWorld Today for coverage of the San Antonio Breast Cancer Symposium.

Affymax Inc.'s peginesatide got a thumbs up from an FDA advisory committee.

Curemark LLC reported positive Phase III data with CM-AT in children with autism.

Genentech Inc./Roche AG's pertuzumab had good Phase III breast cancer data.

Theratechnologies Inc. is halting its chronic obstructive pulmonary disease muscle wasting program and downsizing by 60 percent.

Unigene Laboratories Inc.'s parathyroid hormone was dropped by partner GlaxoSmithKline plc.